A Shining Star in Business Efficiency Rankings
DHG Pharma has been honored in the Top 50 Most Efficient Companies in Vietnam 2025 (TOP50) for the 14th consecutive year, as evaluated by Investment Bridge Magazine and Thien Viet Securities. This marks the 14th year in a row the company has made its mark on this prestigious list, solidifying its position as the leading domestic pharmaceutical company in the country.
“Over the past 14 years, we have witnessed the proud development of DHG Pharma, significantly contributing to the continuous growth of Vietnam’s economy,” emphasized Mrs. Le Thi Bich Ngoc, Editor-in-Chief of Investment Bridge Magazine.
Mrs. Bich Ngoc further noted that the ranking was conducted with the consultation of leading economic experts from Harvard Business School (USA), aiming to identify and honor the most efficient companies on the Vietnamese stock market.
DHG Pharma was highly rated for its business performance over the past three years across all three growth indicators: revenue, return on equity, and earnings per share. These metrics objectively reflect the company’s management capabilities, making it a source of national pride.
At the 2025 Customer Conference themed “Strong Transformation – Steady Growth,” DHG Pharma aims to bring prosperity to its customers and society.
Previously, on August 21, DHG Pharma was also honored by Forbes in the “Top 50 Best Listed Companies in Vietnam” for the 13th consecutive year. Not only recognized for its financial health, DHG Pharma also maintains its leading position in the industry, being one of the three pharmaceutical companies in the Forbes Top 50 2025.
Reflecting on the series of prestigious awards, Mr. Toshiyuki Ishii, CEO of DHG Pharma, shared: “Alongside our growth strategy, DHG Pharma’s achievements today are also due to the immense trust of our customers. Over the past 51 years, we are proud to have the companionship of the largest pharmacy system in the country, steadfastly standing by us through market fluctuations.”
Mr. Toshiyuki Ishii also emphasized that customers are the “extended arm” helping the company reach the top market share in the over-the-counter drug segment. Thanks to this, DHG Pharma has maintained its number one revenue position in the retail pharmaceutical market (excluding vaccines) for five consecutive years from 2020 to 2024, according to IQVIA.
DHG Pharma was highly rated for its business performance over the past three years across all three growth indicators: revenue, return on equity, and earnings per share.
DHG Pharma currently owns two Betalactam and Non-Betalactam factories meeting international standards JAPAN-GMP and EU-GMP, reinforcing its vision of producing “international quality domestic drugs.” In addition to over 150 products manufactured at these factories and production lines, the company is also expanding and transferring many products from Taisho Group (Japan) to serve the domestic market.
Betalactam and Non-Betalactam factories meeting international standards JAPAN-GMP and EU-GMP.
“We expect products manufactured on production lines meeting Japanese and European standards to propel DHG Pharma closer to and more connected with our customers. In every step, DHG remains committed to quality, reputation, and dedication to delivering sustainable value to partners and society,” said CEO Toshiyuki Ishii.
Dual standards JAPAN-GMP and EU-GMP affirm DHG Pharma’s top-tier quality.
Recognition in these prestigious awards has affirmed DHG Pharma’s exceptional management capabilities and commitment to sustainable development. Over the past half-century, DHG Pharma has consistently aimed not only to develop its business but also to actively contribute to the community through social welfare programs, environmental protection, education, and healthcare.
Alongside strengthening its digital transformation strategy and enhancing customer experience with various policies and convenient services, DHG Pharma focuses on investing in human resource development, building a professional team to meet the increasingly high demands of the market and international integration.
In its 51-year journey of maintaining trust, DHG Pharma is committed to providing high-quality products and services, fulfilling the aspiration for a healthier and more beautiful life.
Nam A Bank Secures Spot in Vietnam’s Top 50 Most Efficiently Operated Companies
On September 27th, at the 2025 Corporate Governance Conference, Nam A Bank (HOSE: NAB) was honored among Vietnam’s Top 50 Most Effective Companies in 2025. This recognition rightfully acknowledges the relentless efforts of Nam A Bank’s entire workforce as the bank approaches its 33rd anniversary (October 21, 1992 – October 21, 2025).
“13 Years Running: DHG Pharma’s Stellar Performance in Vietnam’s Top 50 Listed Companies.”
DHG Pharma cements its pioneering position in the pharmaceutical industry, earning the prestigious Forbes recognition as one of the “Top 50 Best Listed Companies in Vietnam” for the 13th consecutive year.
The Struggling Real Estate Firm’s New Venture: A Bold Move into Pharmaceuticals
NRC Group JSC has had its fair share of challenges, but the company is now turning a new leaf with the establishment of NRC Pharma Co., Ltd. With a diverse range of 24 business sectors, NRC Pharma is poised to become a powerhouse in the industry. From cosmetics and pharmaceuticals to wholesale vaccine distribution and healthcare products, NRC Pharma is committed to delivering a wide array of quality products and services to its customers.
Revolutionizing the Industry: NRC Expands Horizons with a New Name and Venture into Pharmaceuticals
The Board of Directors of NRC Corporation (HNX: NRC) has approved the establishment of NRC Pharma LLC with a chartered capital of VND 50 billion. The new subsidiary will be headquartered in Tan Dinh Ward, Ho Chi Minh City, and NRC will contribute the entire capital to this new venture.
